In Re: Zetia (Ezetimibe) Antitrust Litigation

Track this case

Case overview

Case Number:

2:18-md-02836

Court:

Virginia Eastern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Rebecca Beach Smith

Firms

Companies

Sectors & Industries:

April 27, 2023
Merck Says It Paid $573M To Settle Zetia Antitrust Case

Pharmaceutical giant Merck & Co. Inc. paid $573 million to settle antitrust claims this month over allegations it conspired with Glenmark Pharmaceuticals to delay the launch of generic versions of the blockbuster cholesterol drug Zetia, according to first-quarter financial results released Thursday.
April 24, 2023
Merck, Glenmark Cut Deal With Last Group Of Zetia Buyers

Drug companies Merck & Co. Inc. and Glenmark Pharmaceuticals on Monday settled with a group of retail pharmacies, narrowly avoiding a jury trial over allegations they conspired to keep a cheaper version of the cholesterol drug Zetia off the market more than two decades ago.
April 20, 2023
Merck, Glenmark Cut Deal With End Payors Before Zetia Trial

Drug companies Merck and Glenmark Pharmaceuticals have reached their second settlement during jury selection for a trial on claims of an anticompetitive pay-for-delay settlement in 2010 over the cholesterol drug Zetia, according to court records, leaving just one plaintiffs group.
April 18, 2023
Merck, Glenmark Settle With Direct Purchasers In Zetia Case

Drug companies Merck and Glenmark Pharmaceuticals have settled a group of direct purchasers' claims that they gouged drug buyers via an anti-competitive 2010 pay-for-delay patent settlement, leaving one fewer group of plaintiffs just as jury selection in a highly anticipated trial is set to kick off, according to court records.
April 17, 2023
What To Watch In Pay-For-Delay Trial Against Merck, Glenmark

Merck and generic-drug maker Glenmark are set this week to fight multidistrict litigation claims that they gouged buyers of Merck’s blockbuster cholesterol drug Zetia by forging a pay-for-delay deal in 2010. Law360 breaks down the issues and stakes in this rare trial.
April 13, 2023
Covington Partner Must Testify Live In Zetia Trial, Judge Told

Drug buyers seeking billions in damages in an antitrust pay-for-delay trial against pharma companies Merck and Glenmark urged a D.C. federal judge Wednesday to force Covington & Burling partner Timothy Hester to livestream testimony, citing the finding of the trial's presiding judge that Hester is a "key" witness.
April 12, 2023
Merck, Glenmark Can Introduce 'Justifications' In Zetia Trial

Merck and Glenmark will be able to tell a jury the reasons they believe their decision to delay generic competition for the cholesterol medication Zetia was actually good for consumers after a Virginia federal magistrate said the pharmaceutical companies' reasons weren't illegal.
March 15, 2023
Judge Refuses To Split Upcoming Zetia Antitrust Trial

An upcoming trial on claims accusing Merck and Glenmark of conspiring to delay generic competition for the cholesterol medication Zetia will include only one phase after a Virginia federal judge rejected a bid from retailers for a three-phase, two-jury process.
March 08, 2023
Zetia Buyers Face Tough Road For Bid To Split Up Trial

A Virginia federal magistrate judge signaled considerable skepticism during a hearing Wednesday for a bid from retailers such as Walgreens and Albertsons for a three-phase, two jury process for an upcoming trial accusing Merck and Glenmark of conspiring to delay generic competition for branded cholesterol medication Zetia.
March 01, 2023
Some Zetia Buyers No Longer Want Split Trial

The push to split up an upcoming jury trial accusing Merck and Glenmark of conspiring to delay generic competition for branded cholesterol medication Zetia got more complicated with filings from wholesalers and health plans dropping the request that still remains pending from retailers such as Walgreens and Albertsons.

← Previous
1
2
3
4
5
6
Next →